A Phase I Study of PCUR-101 in Combination With Androgen Suppression Therapy in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
Latest Information Update: 05 Nov 2021
At a glance
- Drugs PCUR 101 (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Sponsors Pellficure Pharmaceuticals
- 05 Mar 2020 Status changed from active, no longer recruiting to discontinued.
- 26 Aug 2019 Status changed from recruiting to active, no longer recruiting.
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology